Farrar D J
Department of Cardiac Surgery, California Pacific Medical Center, San Francisco 94115.
J Heart Lung Transplant. 1994 Jan-Feb;13(1 Pt 1):93-100; discussion 100-1.
Approximately two-thirds of patients implanted with ventricular assist devices recover sufficiently to requalify for heart transplantation, and the other one-third die of complications that are often secondary to delayed ventricular assist device implantation and subsequent end-organ failure. To determine whether any preoperative predictors of survival exist, univariate statistics and multivariate stepwise logistic regression analysis were performed on pre-ventricular assist device demographics, hemodynamics, and blood chemistry in 186 patients receiving Thoratec ventricular assist devices (Thoratec Laboratories Corp., Berkeley, Calif.) while awaiting transplantation. The duration of circulatory support averaged 19.6 days (maximum, 226 days). One hundred thirty-seven patients (74%) received biventricular support, 47 received isolated left ventricular assist devices, and two received right ventricular assist devices. The average blood flow was 5.0 +/- 0.9 L/min. One hundred eighteen patients (63%) ultimately received heart transplants, of whom 96 patients were discharged. Age, gender, weight, and diagnosis were not related to survival, nor were preoperative cardiac index, pulmonary capillary wedge pressure, intraaortic balloon pumps, or cardiac arrests. Pre-ventricular assist device creatinine levels (p = 0.24) and total bilirubin levels (p = 0.09) were not significant, but blood urea nitrogen level (p = 0.02) and previous operations (p = 0.05) were related to survival, using univariate techniques. Patients with cardiac operations more than 30 days previously had the lowest survival-to-transplantation (39%) compared with patients with no previous operations (67%) or operations within the previous 30 days (61%). Blood urea nitrogen level was the only parameter found to be significant (p = 0.016) in a multivariate model.(ABSTRACT TRUNCATED AT 250 WORDS)
接受心室辅助装置植入的患者中,约三分之二恢复良好,有资格再次接受心脏移植,另外三分之一死于并发症,这些并发症通常继发于心室辅助装置植入延迟及随后的终末器官衰竭。为了确定是否存在术前生存预测因素,对186例等待移植期间接受Thoratec心室辅助装置(Thoratec实验室公司,加利福尼亚州伯克利)的患者,在植入心室辅助装置前的人口统计学、血流动力学和血液化学指标进行了单因素统计及多因素逐步逻辑回归分析。循环支持的平均持续时间为19.6天(最长226天)。137例患者(74%)接受双心室支持,47例接受孤立左心室辅助装置,2例接受右心室辅助装置。平均血流量为5.0±0.9L/分钟。118例患者(63%)最终接受了心脏移植,其中96例患者出院。年龄、性别、体重和诊断与生存无关,术前心脏指数、肺毛细血管楔压、主动脉内球囊泵或心脏骤停也与生存无关。使用单因素分析方法,植入心室辅助装置前的肌酐水平(p = 0.24)和总胆红素水平(p = 0.09)无统计学意义,但血尿素氮水平(p = 0.02)和既往手术史(p = 0.05)与生存相关。与无既往手术史(67%)或既往30天内有手术史(61%)的患者相比,既往手术超过30天的患者移植前生存率最低(39%)。在多因素模型中,血尿素氮水平是唯一具有统计学意义的参数(p = 0.016)。(摘要截短至250字)